Proteomics International Says Results Validate Blood Test for Diagnosis of Esophageal Cancer, Shares Jump 7%

MT Newswires Live

Sep 08, 2025

Proteomics International Laboratories (ASX:PIQ) said results from a study showed that its PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma with high accuracy, according to a Monday Australian bourse filing.

The study analyzed 350 people across two independent cohorts. Cohort A compared 89 healthy controls with esophageal adenocarcinoma samples of known stage, while cohort B compared 40 negative controls with unstaged esophageal adenocarcinoma and Barrett's Esophagus samples.

The blood test showed diagnostic accuracy for all stages of esophageal cancer. The results showed that the severity of disease is significantly correlated with increasing PromarkerEso test scores.

The study was published online ahead of presentation at the annual ISDE World Congress for Esophageal Diseases in Brisbane.

Its shares jumped 7% in early trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2565753265"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565753265\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565753265?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 08:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565753265","market":"us","top_or_hot":-1,"title":"Proteomics International Says Results Validate Blood Test for Diagnosis of Esophageal Cancer, Shares Jump 7%","media":"MT Newswires Live","content":"<html><body><p> Proteomics International Laboratories (ASX:PIQ) said results from a study showed that its PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma with high accuracy, according to a Monday Australian bourse filing.</p><p>The study analyzed 350 people across two independent cohorts. Cohort A compared 89 healthy controls with esophageal adenocarcinoma samples of known stage, while cohort B compared 40 negative controls with unstaged esophageal adenocarcinoma and Barrett's Esophagus samples.</p><p>The blood test showed diagnostic accuracy for all stages of esophageal cancer. The results showed that the severity of disease is significantly correlated with increasing PromarkerEso test scores.</p><p>The study was published online ahead of presentation at the annual ISDE World Congress for Esophageal Diseases in Brisbane.</p><p>Its shares jumped 7% in early trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Proteomics International Says Results Validate Blood Test for Diagnosis of Esophageal Cancer, Shares Jump 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProteomics International Says Results Validate Blood Test for Diagnosis of Esophageal Cancer, Shares Jump 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-08 08:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Proteomics International Laboratories (ASX:PIQ) said results from a study showed that its PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma with high accuracy, according to a Monday Australian bourse filing.</p><p>The study analyzed 350 people across two independent cohorts. Cohort A compared 89 healthy controls with esophageal adenocarcinoma samples of known stage, while cohort B compared 40 negative controls with unstaged esophageal adenocarcinoma and Barrett's Esophagus samples.</p><p>The blood test showed diagnostic accuracy for all stages of esophageal cancer. The results showed that the severity of disease is significantly correlated with increasing PromarkerEso test scores.</p><p>The study was published online ahead of presentation at the annual ISDE World Congress for Esophageal Diseases in Brisbane.</p><p>Its shares jumped 7% in early trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PIQ.AU","symbol_name":"PROTEOMICS INTERNATIONAL LAB","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2565753265","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565753265","pubTimestamp":1757292681,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Proteomics International Laboratories  said results from a study showed that its PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma with high accuracy, according to a Monday Australian bourse filing.The study analyzed 350 people across two independent cohorts. Cohort A compared 89 healthy controls with esophageal adenocarcinoma samples of known stage, while cohort B compared 40 negative controls with unstaged esophageal adenocarcinoma and Barrett's Esophagus samples.The blood test showed diagnostic accuracy for all stages of esophageal cancer. The results showed that the severity of disease is significantly correlated with increasing PromarkerEso test scores.The study was published online ahead of presentation at the annual ISDE World Congress for Esophageal Diseases in Brisbane.Its shares jumped 7% in early trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PIQ.AU":"PROTEOMICS INTERNATIONAL LAB","BK7508":"医药生物股","BK7048":"生命科学工具和服务"},"translate_title":"Proteomics International表示结果验证了血液测试诊断食道癌的有效性，股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PIQ.AU":0.9},"content_text":"Proteomics International Laboratories (ASX:PIQ) said results from a study showed that its PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma with high accuracy, according to a Monday Australian bourse filing.The study analyzed 350 people across two independent cohorts. Cohort A compared 89 healthy controls with esophageal adenocarcinoma samples of known stage, while cohort B compared 40 negative controls with unstaged esophageal adenocarcinoma and Barrett's Esophagus samples.The blood test showed diagnostic accuracy for all stages of esophageal cancer. The results showed that the severity of disease is significantly correlated with increasing PromarkerEso test scores.The study was published online ahead of presentation at the annual ISDE World Congress for Esophageal Diseases in Brisbane.Its shares jumped 7% in early trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}